Oryzon Genomics — ASH 2025: Promising iadademstat updates
Oryzon Genomics announced the presentation of promising updates for two clinical studies involving iadademstat at the American Society of...
167 Views
Oryzon Genomics — Progression across the pipeline in Q3
Oryzon Genomics has reported its Q325 results, a period characterised by tangible progress across its ongoing clinical programmes. Anticipation...
125 Views
Oryzon Genomics — Progress for iadademstat across the board
Oryzon has announced encouraging updates for iadademstat. In acute myeloid leukaemia (AML), positive data was reported for two programmes,...
128 Views
Oryzon Genomics — Making headway towards Phase III in BPD
Oryzon Genomics has announced that it has received FDA feedback on its plans for the Phase III programme in borderline personality disorder (BPD)...
179 Views
Oryzon Genomics — Foray into sickle cell disease
Oryzon Genomics has announced that the European Medicines Agency (EMA) has provided regulatory clearance for a Phase Ib trial of iadademstat in...
212 Views